JPS5221825B2 - - Google Patents
Info
- Publication number
- JPS5221825B2 JPS5221825B2 JP11876773A JP11876773A JPS5221825B2 JP S5221825 B2 JPS5221825 B2 JP S5221825B2 JP 11876773 A JP11876773 A JP 11876773A JP 11876773 A JP11876773 A JP 11876773A JP S5221825 B2 JPS5221825 B2 JP S5221825B2
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11876773A JPS5221825B2 (enExample) | 1973-10-22 | 1973-10-22 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11876773A JPS5221825B2 (enExample) | 1973-10-22 | 1973-10-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5066972A JPS5066972A (enExample) | 1975-06-05 |
| JPS5221825B2 true JPS5221825B2 (enExample) | 1977-06-13 |
Family
ID=14744550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11876773A Expired JPS5221825B2 (enExample) | 1973-10-22 | 1973-10-22 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5221825B2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57110595U (enExample) * | 1980-12-27 | 1982-07-08 | ||
| US11402381B2 (en) | 2015-10-23 | 2022-08-02 | Roche Diagnostics Operations, Inc. | Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses |
-
1973
- 1973-10-22 JP JP11876773A patent/JPS5221825B2/ja not_active Expired
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57110595U (enExample) * | 1980-12-27 | 1982-07-08 | ||
| US11402381B2 (en) | 2015-10-23 | 2022-08-02 | Roche Diagnostics Operations, Inc. | Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5066972A (enExample) | 1975-06-05 |